IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study
- 234 Downloads
To study if luteal E2 pre-treatment before GnRH antagonist protocol improves IVF/ICSI outcomes compared with standard long GnRH agonist protocol.
A prospective, randomized and controlled study.
ART center of a state public hospital
Two hundred twenty infertile women underwent IVF/ICSI treatments.
Participants received oral Estradiol Valerate 4 mg/day preceding the IVF cycle from day 21 until day 2 of next cycle before GnRH antagonist protocol (E2 pre-treatment group n = 109) or received standard long GnRH agonist protocol as control group (n = 111).
Main outcome measure(s)
Number of oocytes collected, MII oocytes, fertilization, implantation, live birth and early pregnancy rate, and hormone profiles.
E2 pre-treatment exerted a significant suppressive effect on FSH but not LH secretion compared with basal FSH and LH levels. In E2 pre-treatment group serum LH level was significantly higher during COH and serum P was also significantly higher on the day of HCG injection compared with control group. Five patients from E2 pre-treatment group had elevated LH at all time (≥10 IU/L) and also a concomitantly high P (>1 ng/mL). Two of the five women achieved pregnancy but had early pregnancy loss. Overall, IVF/ICSI outcomes such as implantation, clinical pregnancy and live birth rates were similar between E2 pre-treatment and control groups.
Luteal E2 pre-treatment before GnRH antagonist protocol significantly increases serum LH level and incidence rate of premature LH but no significant effect is observed on implantation, clinical pregnancy, live birth and early pregnancy loss rates compared with long GnRH agonist protocol. However, more studies in large numbers of cycles are needed to confirm that increased serum LH level by E2 pre-treatment during COH has no negative effect on the IVF/ICSI outcomes.
KeywordsFSH Estradiol pre-treatment Controlled ovarian hyperstimulation IVF
The authors thank Dr. De Yi Liu from the University of Melbourne, Australia, for revising the final draft of the manuscript.
- 4.Opsahl MS, Blauor KL, Black SH, Lincoln SR, Thorell L, Sherins RJ. The number of embryos available for transfer predicts successful pregnancy outcome in women over 39 years with normal ovarian hormonal reserve testing. J Assist Reprod Genet. 2001;18:551–6. doi: 10.1023/A:1011906024170.PubMedCrossRefGoogle Scholar
- 5.Fanchin R, Cunha-Filho JS, Schonauer LM, Kadoch IJ, Cohen-Bacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation. Fertil Steril. 2003;79:316–21. doi: 10.1016/S0015-0282(02)04574-0.PubMedCrossRefGoogle Scholar
- 7.Fanchin R, Cunha-Filho JS, Schonauer LM, Righini C, de Ziegler D, Frydman R. Luteal estradiol administration strengthens the relationship between day 3 follicle-stimulations hormone and inhibin B levels and ovarian follicular status. Fertil Steril. 2003;79:585–9. doi: 10.1016/S0015-0282(02)04757-X.PubMedCrossRefGoogle Scholar
- 9.Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab. 1996;81:1038–45. doi: 10.1210/jc.81.3.1038.PubMedCrossRefGoogle Scholar
- 11.Durnerin-Cedrin I, Bstandig B, Parneix L, et al. Effects of oral comfraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod. 2007;22:109–16. doi: 10.1093/humrep/del340.CrossRefGoogle Scholar
- 13.Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone in effective, safe and convenient: results of a controlled, randomize, multi-centre trial. The European Orgalutran Study Group. Hum Reprod. 2000;15:1490–8. doi: 10.1093/humrep/15.7.1490.PubMedCrossRefGoogle Scholar
- 15.Huime JAF, van Loenen ACD, Schats R, McDonnell J, Hompes PGA, Schoemaker J, et al. Dose-finding study of daily GnRH antagonist for the prevention of premature LHsurges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Hum Reprod. 2005;20:359–67.Google Scholar
- 16.Kolibianakis EM, Zikopoulous K, Schiettecatte J, Smita J, Tournaye H, Camus M, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod. 2004;19:2490–6. doi: 10.1093/humrep/deh471.PubMedCrossRefGoogle Scholar
- 17.Rombauts L, Healy D, Norman RJ. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. On behalf of the Orgalutran Scheduling Study Group. Hum Reprod. 2006;21:95–103. doi: 10.1093/humrep/dei302.Google Scholar
- 18.Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is hv+mcnkjjassociatoal with a reduced chance of pregnancy. Fertil Steril. 2003;79:873–80. doi: 10.1016/S0015-0282(02)04920-8.PubMedCrossRefGoogle Scholar